NewCardio, Inc. (NWCI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNewCardio, Inc. (NWCI) trades at $0.0001. NewCardio, Inc. focuses on developing and commercializing software platform technology solutions for non-invasive cardiovascular disease diagnosis and cardiac safety assessment. Sector: Healthcare.
Price as of · Last analyzed: Jun 1, 2026Analyst Coverage for NWCI: NWCI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
NewCardio, Inc. (NWCI) Healthcare & Pipeline Overview
NewCardio, Inc., operating in the medical devices sector, specializes in cardiac diagnostic solutions, offering proprietary software for non-invasive cardiovascular disease monitoring and drug safety assessment. Their technology provides real-time, 3-D analysis of heart activity via standard ECG, positioning them in a niche market within the broader healthcare landscape.
What Is the Investment Thesis for NWCI?
NewCardio, Inc. presents a high-risk, high-reward investment profile within the medical devices sector. The company's focus on innovative cardiac diagnostic software, including QTinno and CardioBip, addresses a critical need for improved CVD monitoring and drug safety assessment. However, with a negative profit margin of -4466.2% and a small market capitalization, the company's financial stability is a significant concern. Growth catalysts include potential regulatory approvals for its products and strategic partnerships with pharmaceutical companies for cardiac safety assessments. The company's success hinges on its ability to commercialize its technology and secure funding to sustain operations.
Based on FMP financials and quantitative analysis
NWCI Key Highlights
Market Cap of $0.00B indicates a micro-cap company with limited financial resources.
- Profit Margin of -4466.2% highlights significant losses and operational inefficiencies.
- Gross Margin of 40.8% suggests potential profitability if operating expenses are managed effectively.
- Beta of -120.60 indicates an inverse correlation with the market, which is unusual and may reflect company-specific factors rather than market trends.
- No Dividend Yield reflects the company's focus on reinvesting earnings for growth, typical for early-stage companies.
Who Are NWCI's Competitors?
NWCI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.82 | -1.41% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $7.74 | -4.44% | $5.63M | 30 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.76 | +1.18% | $32.1M | — |
| SNWV SANUWAVE Health, Inc. | $4.82 | -1.04% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $3.03 | +1.68% | $49.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.83 | +2.82% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.71 | -0.59% | $82.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.52 | -0.98% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NWCI's Key Strengths?
Proprietary software platform for cardiac diagnostics.
- Focus on non-invasive and real-time analysis.
- Potential for automated solutions to improve efficiency.
- Experienced management team in cardiac technology.
What Are NWCI's Weaknesses?
Limited financial resources and negative profit margin.
- Small market capitalization and low trading volume.
- Dependence on regulatory approvals for product commercialization.
- Limited brand recognition and market presence.
What Are the Key Risks for NWCI?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Limited financial resources and negative profit margin.
- Competition from established medical device manufacturers.
- Technological obsolescence and rapid innovation.
- Regulatory hurdles and compliance requirements.
- Economic downturn and reduced healthcare spending.
What Are NWCI's Competitive Advantages?
- Proprietary software platform technology.
- Specialized expertise in cardiac diagnostics.
- Potential for regulatory approvals and patents.
- First-mover advantage in niche market segments.
What Does NWCI Do?
Founded in 2004 and based in Branchburg, New Jersey, NewCardio, Inc. is a cardiac diagnostic and services company focused on the research, development, and commercialization of proprietary software platform technology solutions. These solutions are designed for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's core technology platform enables real-time and 3-D analysis of the heart's electrical activity, utilizing standard 12-lead electrocardiogram (ECG) electrodes applied to the body surface. NewCardio's developing products include QTinno, an automated cardiac safety solution intended to replace manual or semi-automated methodologies with algorithms that automatically measure, analyze, and report on ECG data. Another key product is CardioBip, a mobile ECG transtelephonic system that comprises a mobile ECG recording and transmitting device, coupled with web-enabled software for data reception, processing, and analysis. The company is also developing my3KG, a software application designed to assess cardiac electrical activity in both time and space. NewCardio aims to improve the efficiency and accuracy of cardiac diagnostics through innovative software solutions.
What Products and Services Does NWCI Offer?
- Develop proprietary software platform technology solutions for cardiac diagnostics.
- Offer non-invasive diagnosis and monitoring of cardiovascular disease (CVD).
- Provide cardiac safety assessment of drugs under development.
- Offer real-time and 3-D analysis of the heart's electrical activity.
- Develop QTinno, an automated cardiac safety solution.
- Develop CardioBip, a mobile ECG transtelephonic system.
- Develop my3KG, a software application to assess cardiac electrical activity in time and space.
How Does NWCI Make Money?
- Develop and sell cardiac diagnostic software solutions.
- Generate revenue through licensing agreements with pharmaceutical companies.
- Offer cardiac monitoring services to healthcare providers.
- Potentially generate revenue through subscription-based access to its software platforms.
What Industry Does NWCI Operate In?
NewCardio, Inc. operates within the medical devices industry, a sector characterized by rapid technological advancements and stringent regulatory requirements. The market for cardiac diagnostic devices is driven by the increasing prevalence of cardiovascular diseases and the growing demand for non-invasive monitoring solutions. Competition includes established medical device manufacturers and smaller, specialized technology companies. NewCardio's focus on software-based solutions and real-time analysis positions it within a niche segment of the market, potentially offering a competitive advantage if its technology proves superior and gains regulatory approval.
Who Are NWCI's Key Customers?
- Pharmaceutical companies requiring cardiac safety assessments.
- Hospitals and clinics providing cardiac care.
- Cardiologists and other healthcare professionals.
- Patients requiring remote cardiac monitoring.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 3 purchases, 0 sales, 9 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Key Financial Metrics
Return on equity for NewCardio, Inc. stands at 496.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.72 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
NewCardio, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
NewCardio, Inc. has beaten Wall Street's EPS estimate in 3 of its last 5 reported quarters — more hits than misses. Reported results have landed about 70.5% below estimates on average.
Company Profile
NewCardio, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Branchburg, US. The company is led by CEO Jess Emery Jones. NWCI has traded publicly since 2008.
NWCI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
NWCI Latest News
No recent news available for NWCI.
NWCI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NWCI.
Price Targets
Wall Street price target analysis for NWCI.
NWCI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NWCI; grades run from A+ (80-100) to F (below 30).
Leadership: Jess Emery Jones
CEO
Jess Emery Jones serves as the CEO of NewCardio, Inc. His background includes managing teams and overseeing the operations of the company. While specific details on his prior experience and education are not provided, his leadership is critical to guiding NewCardio's strategic direction and product development efforts. His expertise is essential for navigating the complexities of the medical device industry and securing funding for the company's growth initiatives.
Track Record: Under Jess Emery Jones' leadership, NewCardio, Inc. has focused on the development and commercialization of its proprietary software platform technology. Key milestones include the development of QTinno, CardioBip, and my3KG. His leadership is crucial for navigating the challenges of a micro-cap company with limited resources and a negative profit margin.
NWCI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NewCardio, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, financial distress, or regulatory issues. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in NWCI.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The lack of readily available financial information makes it difficult to assess the company's true financial condition.
- Low Liquidity: The low trading volume and wide bid-ask spreads can make it challenging to buy or sell shares.
- Regulatory Scrutiny: OTC Other companies are subject to less regulatory oversight, increasing the risk of fraud or mismanagement.
- Going Concern Risk: The company's negative profit margin and limited financial resources raise concerns about its ability to continue operating.
- Dilution Risk: The company may need to issue additional shares to raise capital, which could dilute existing shareholders' ownership.
- Verify the company's legal standing and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's products and technology.
- Understand the company's competitive landscape.
- Determine the company's capital structure and debt obligations.
- Consult with a qualified financial advisor.
- Focus on cardiac diagnostic software development.
- Development of QTinno, CardioBip, and my3KG.
- CEO Jess Emery Jones is in place.
- Company has been in operation since 2004.
- Company has 10 employees.
NewCardio, Inc. Healthcare Stock: Key Questions Answered
What do analysts say about NWCI stock?
As of 2026-06-01, there is no available analyst coverage or consensus on NewCardio, Inc. (NWCI) stock, likely due to its OTC listing and small market capitalization.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC market investments carry significant risks.
- Analyst coverage is non-existent.